This page uses content from Wikipedia and is licensed under CC BY-SA.

Levobetaxolol

Levobetaxolol
Levobetaxolol structure.svg
Levobetaxolol-fill.png
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
topical (ophthalmic)
ATC code
  • none
Pharmacokinetic data
Elimination half-life20 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H29NO3
Molar mass307.427 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Indications

It is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension.[1]

Effect

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated with bradycardia and hypertension.[citation needed]

History

Levobetaxolol was developed in the 1980s.[1] It was FDA approved in 2000.[2]

References

  1. ^ a b c Quaranta, Luciano; Turano, Raffaele; Pizzolante, Teodoro (2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology (Auckland, N.Z.). 1 (2): 93–97. ISSN 1177-5467. PMC 2704505. PMID 19668496.
  2. ^ "Betaxon New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 11 April 2019.